Details of the Drug

General Information of Drug (ID: DMK56G0)

• Drug Name: Bexagliflozin
• Synonyms: UNII-EY00JF42FV; EGT-1442; Bexagliflozin [USAN]; THR-1442; EY00JF42FV; CHEMBL1808388; 1118567-05-7; Bexagliflozin (USAN); D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(2-(cyclopropyloxy)ethoxy)phenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(2-cyclopropoxyethoxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropyloxy)ethoxy]phenyl]methyl]phenyl]-D-glucitol; EGT1442; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[2-(cyclopropylo

Indication

Disease Entry	ICD 11	Status	REF
Type 2 diabetes	5A11	Approved	[1]
Type-2 diabetes	5A11	Phase 3	[2]

• Affected Organisms: Humans and other mammals
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 464.9
  Logarithm of the Partition Coefficient (xlogp); 2.4
  Rotatable Bond Count (rotbonds); 9
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 7
• Chemical Identifiers:
  Formula: C24H29ClO7
  IUPAC Name: (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-(2-cyclopropyloxyethoxy)phenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
  Canonical SMILES: C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
  InChI: InChI=1S/C24H29ClO7/c25-19-8-3-15(24-23(29)22(28)21(27)20(13-26)32-24)12-16(19)11-14-1-4-17(5-2-14)30-9-10-31-18-6-7-18/h1-5,8,12,18,20-24,26-29H,6-7,9-11,13H2/t20-,21-,22+,23-,24+/m1/s1
  InChIKey: BTCRKOKVYTVOLU-SJSRKZJXSA-N
• Cross-matching ID:
  PubChem CID: 25195624
  ChEBI ID: CHEMBL1808388
  CAS Number: 1118567-05-7
  UNII: EY00JF42FV
  DrugBank ID: DB12236
  TTD ID: D0OR3G
  VARIDT ID: DR01083
• Drug-Molecule Activity Atlas (DMA)NEW: Click to Jump to the Detailed DMA Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
SLC5A2 messenger RNA (SLC5A2 mRNA)	TTF8JAT	SC5A2_HUMAN	Inhibitor	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
UDP-glucuronosyltransferase 1A9	OTPCHAFX	UD19_HUMAN	Regulation of Drug Effects	[3]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 05 Endocrine, nutritional or metabolic disease
• Disease Class: ICD-11: 5A11 Type 2 diabetes mellitus
• The Studied Tissue: Liver tissue
• The Studied Disease: Type 2 diabetes [ICD-11:5A11]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
SLC5A2 messenger RNA (SLC5A2 mRNA)	DTT	SLC5A2	3.26E-01	-0.09	-0.37

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 214373.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Bexagliflozin: First Approval. Drugs. 2023 Apr;83(5):447-453. doi: 10.1007/s40265-023-01848-x.